Tumor Associated Neutrophils as a Biomarker of Chemo-immunotherapy Response in Locally Advanced Non-small Cell Lung Cancer : a Model Based on Neoadjuvant Strategy

Inclusion Criteria: * Age ≥ 18 years. * Resectable non-small cell lung cancer (NSCLC), stage IIA to IIIB. * Lymph node status obtained by Positron Emission Tomoscintigraphy (PET)-scanner, confirmation of lymph node status by optional histological sampling (mediastinoscopy, thoracoscopy, echo-endoscopy). * No secondary lesions in the cerebrum or extra-cerebrum confirmed on brain MRI, PET scanner +/- injected cerebro-thoraco-abdomino-pelvic scanner. * Neoadjuvant immunochemotherapy strategy validated by a multidisciplinary consultation meeting (RCP) prior to the start of treatment. * Lung function compatible with thoracic surgery, patient meets surgical and anesthetic criteria for operability * Measurable disease according to RECIST criteria version 1.1 Exclusion Criteria: * Previous systemic treatment for the same CBNPC. * Diagnosis of another solid tumor within the last 3 years, ‡ excluding non melanoma cutaneous and cervical carcinomas . * Contraindication to immunotherapy. * Non-objection to participate in research not collected. * Patients unable to read and/or write. * Inability to monitor patient during study period * Persons unable to express their consent. * Not affiliated to a social security scheme. * Persons under court protection. * Persons participating in another research study with an ongoing exclusion period. * Pregnant women